← Aditya Birla Sun Life Mutual Fund

Aditya Birla Sun Life Nifty Healthcare ETF

Index/ETF Data as of Oct 2026 Comparing Sep 2026 → Oct 2026
Share: WhatsApp X
Stocks Held
20
Oct 2026
Equity Holdings
₹80.00 Cr
Equity only, excl. debt & cash
Top 5 Weight
49.9%
High concentration
Top 10 Weight
76.3%
High concentration
Changes
20
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
81.8% of portfolio
Launch Date
08 Oct 2021
5 years old
📋 What Happened This Month Among existing holdings, Laurus Labs Limited saw the biggest increase — now at 8.12% of the portfolio. Sun Pharmaceutical Industries Limited was trimmed the most, now at 16.32%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 81.8%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Aug 2026 → Sep 2026
Sector Prev Curr ▼ Delta
Pharmaceuticals & Biotechnology 80.7% 81.1% ▲ +0.4%
Healthcare Services 19.3% 18.9% ▼ -0.4%
Sep 2026 → Oct 2026
Sector Prev Curr ▼ Delta
Pharmaceuticals & Biotechnology 81.1% 81.8% ▲ +0.7%
Healthcare Services 18.9% 18.2% ▼ -0.7%
↑
Biggest Add
Laurus Labs Limited
+1.31% · now 8.12%
↓
Biggest Trim
Sun Pharmaceutical Industries Limited
-0.68% · now 16.32%

What Changed in the Portfolio This Month?

Comparing Sep 2026 → Oct 2026

Sep 2026 → Oct 2026
↑ 7 Increased ↓ 13 Decreased
#StockSectorSep 2026Oct 2026Change
1
Laurus Labs Limited
₹6.50 Cr
Pharmaceuticals & Biotechnology 6.81% 8.12% +1.31%
2
Dr. Reddy's Laboratories Limited
₹5.72 Cr
Pharmaceuticals & Biotechnology 6.64% 7.15% +0.51%
3
Divi's Laboratories Limited
₹8.63 Cr
Pharmaceuticals & Biotechnology 10.46% 10.78% +0.32%
4
Zydus Lifesciences Limited
₹2.14 Cr
Pharmaceuticals & Biotechnology 2.54% 2.68% +0.14%
5
Gland Pharma Limited
₹1.71 Cr
Pharmaceuticals & Biotechnology 2.04% 2.14% +0.10%
6
Apollo Hospitals Enterprise Limited
₹6.04 Cr
Healthcare Services 7.45% 7.54% +0.09%
7
Cipla Limited
₹5.38 Cr
Pharmaceuticals & Biotechnology 6.69% 6.73% +0.04%
#StockSectorSep 2026Oct 2026Change
1
Sun Pharmaceutical Industries Limited
₹13.06 Cr
Pharmaceuticals & Biotechnology 17.00% 16.32% -0.68%
2
Max Healthcare Institute Limited
₹4.44 Cr
Healthcare Services 6.11% 5.55% -0.56%
3
Torrent Pharmaceuticals Limited
₹4.71 Cr
Pharmaceuticals & Biotechnology 6.26% 5.89% -0.37%
4
Biocon Limited
₹1.70 Cr
Pharmaceuticals & Biotechnology 2.28% 2.13% -0.15%
5
Krishna Institute Of Medical Sciences Limited
₹1.30 Cr
Healthcare Services 1.76% 1.62% -0.14%
6
Lupin Limited
₹3.39 Cr
Pharmaceuticals & Biotechnology 4.35% 4.23% -0.12%
7
Glenmark Pharmaceuticals Limited
₹2.40 Cr
Pharmaceuticals & Biotechnology 3.10% 3.00% -0.10%
8
Alkem Laboratories Limited
₹2.14 Cr
Pharmaceuticals & Biotechnology 2.77% 2.68% -0.09%
9
Fortis Healthcare Limited
₹2.78 Cr
Healthcare Services 3.54% 3.47% -0.07%
10
Abbott India Limited
₹92.54 L
Pharmaceuticals & Biotechnology 1.22% 1.16% -0.06%

What Stocks Does This Fund Hold?

20 stocks — Oct 2026

# Stock Sector Cap Weight & Value
1
₹13.06 Cr
Pharmaceuticals & Biotechnology
16.32%
2
₹8.63 Cr
Pharmaceuticals & Biotechnology
10.78%
3
₹6.50 Cr
Pharmaceuticals & Biotechnology
8.12%
4
₹6.04 Cr
Healthcare Services
7.54%
5
₹5.72 Cr
Pharmaceuticals & Biotechnology
7.15%
6
₹5.38 Cr
Pharmaceuticals & Biotechnology
6.73%
7
₹4.71 Cr
Pharmaceuticals & Biotechnology
5.89%
8
₹4.44 Cr
Healthcare Services
5.55%
9
₹3.39 Cr
Pharmaceuticals & Biotechnology
4.23%
10
₹3.22 Cr
Pharmaceuticals & Biotechnology
4.03%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
→
🏦 Aditya Birla Sun Life Mutual Fund — Portfolio & Holdings
See all funds managed by Aditya Birla Sun Life Mutual Fund — conviction stocks, monthly entries & exits
→

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.